recombinant EGF/CRM-197 vaccine (Shanghai Humantech Biotechnology)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namerecombinant EGF/CRM-197 vaccine (Shanghai Humantech Biotechnology)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > ToxinVaccines > Application > Therapeutic vaccine
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Humantech Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Humantech Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A